AIA Am., Inc. v. Avid Radiopharmaceuticals

• Decision Date: 10 August 2017
• Docket Number: 2016-2647
• Citation: 866 F.3d 1369
• Parties: AIA AMERICA, INC., fka Alzheimer's Institute of America, Inc., Plaintiff-Appellant v. AVID RADIOPHARMACEUTICALS, Defendant-Appellee Trustees of the University of Pennsylvania, University of South Florida Board of Trustees, Defendants
• Court: U.S. Court of Appeals — Federal Circuit

866 F.3d 1369

AIA AMERICA, INC., fka Alzheimer's Institute of America, Inc., Plaintiff-Appellant

v.AVID RADIOPHARMACEUTICALS, Defendant-Appellee

Trustees of the University of Pennsylvania, University of South Florida Board of Trustees, Defendants

2016-2647

United States Court of Appeals, Federal Circuit.

Decided: August 10, 2017

Peter Buckley , Fox Rothschild, LLP, Philadelphia, PA, argued for plaintiff-appellant.

Lawrence Scott Burwell , Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Reston, VA, argued for defendant-appellee. Also represented by Charles E. Lipsey ; Laura Pollard Masurovsky , Washington, DC; Manisha A. Desai , Eli Lilly and Company, Indianapolis, IN.

Before Newman, Lourie, and Hughes, Circuit Judges.

Hughes, Circuit Judge.

AIA America, Inc. appeals the district court's award of attorney's fees to Avid Radiopharmaceuticals and the Trustees of the University of Pennsylvania. Because the Seventh Amendment right to a jury trial does not apply to requests for attorney's fees under § 285 of the Patent Act, the district court did not err by making factual findings not foreclosed by the jury's verdict on standing, and AIA's due process rights were not violated, we affirm.

I

AIA America, Inc. sued Avid Radiopharmaceuticals and the Trustees of the University of Pennsylvania (collectively, Avid) for infringement of U.S. Patent Nos. 5,455,169 and 7,538,258. The patents are generally directed to research technologies stemming from the discovery of the "Swedish mutation," a genetic mutation that is associated with early-onset familial Alzheimer's disease. For example, the '169 patent claims a nucleic acid encoding a human amyloid precursor protein with the Swedish mutation. Dr. Michael J. Mullan is named as the sole inventor of both patents.

Avid, in response, alleged that AIA lacked standing to assert the '169 and '258 patents. According to Avid, Ronald Sexton, AIA's founder, and Dr. Mullan, the purported sole inventor, orchestrated a scheme to appropriate for themselves inventions from Imperial College (Imperial) in London and the University of South Florida (USF).

Avid argued that the scheme began when members of Dr. John Hardy's Imperial research group (including Dr. Mullan, then a Ph.D. student) made the groundbreaking discovery of one of the first gene mutations that causes Alzheimer's disease. The gene mutation was later called the "London Mutation." Under a sponsored research agreement, Imperial gave options to that discovery to Athena, a pharmaceutical company.

Dr. Hardy and his team believed the Athena agreement undervalued their research. Soon thereafter, Mr. Sexton, a Kansas City businessman who had no experience in scientific research but saw a business opportunity for himself, offered Dr. Hardy and his team a better deal than they had with Athena. Initially, Dr. Hardy and his team attempted to undermine the agreement with Athena by misrepresenting the origins of their work on the London Mutation. This attempt failed when Imperial determined that it owned the discovery under United Kingdom law by its employment of the inventors. Dr. Hardy, his team, and Mr. Sexton then "decided to make sure [they] didn't give anything else away." J.A. 2759:13–14.

Therefore, when Dr. Hardy started investigating Alzheimer's mutations in Swedish families and realized the data was "screaming" that there was a mutation in the DNA, he decided not to identify the actual sequence of the mutation at Imperial. JA 2790:9–18. Instead, he sent the DNA to Dr. Mullan, who had graduated from Imperial and moved to USF, so the DNA could be sequenced there. To hide the involvement of Dr. Hardy and the Imperial researchers, the resulting patent application on the Swedish mutation was filed in Dr. Mullan's name alone.

To further their scheme, Mr. Sexton, Dr. Hardy, and Dr. Mullan sent false letters to Imperial denying Dr. Hardy's involvement in the discovery. The group also misled USF into believing that this discovery related to prior research to which Imperial had rights, thereby securing USF's signature on a letter waiving USF's ownership of the newly discovered Swedish mutation. After the patent application was filed, it was immediately assigned to Sexton's newly-formed company, AIA.

AIA, meanwhile, maintained that Dr. Mullan was properly named the sole inventor of the '169 and '258 patents and that Dr. Mullan's employer, USF, waived any ownership rights in the patents.

The district court ordered targeted discovery and held a jury trial on AIA's standing, in which twelve witnesses testified and over 200 exhibits were introduced. As part of the trial, Dr. Hardy testified about the conspiracy by which, he, Dr. Mullan, and Mr. Sexton denied Imperial and USF rights in the Swedish mutation. The jury determined that USF did not knowingly and intentionally waive its ownership rights to the Swedish mutation and that Dr. Hardy was a co-inventor. Based on the jury's verdict, the district court found AIA lacked standing to assert the '169 and '258 patents and entered judgment in favor of Avid. We summarily affirmed that decision. Alzheimers Inst. of Am., Inc. v. Avid Radiopharmaceuticals , 560 Fed.Appx. 996 (Fed. Cir. 2014).

Avid subsequently moved for attorney's fees. The district court allowed the parties to submit extensive briefing, evidence, and declarations on the issue of fees. After holding a hearing in which AIA was allowed to present arguments in opposition to the motion, the court awarded fees in the amount of $3,943,317.70 to Avid. AIA appeals the award of attorney's fees, but not the amount awarded. We have jurisdiction under 28 U.S.C. § 1295(a)(1) (2012).

II

We first address AIA's argument that the Seventh Amendment requires a jury trial to decide the facts forming the basis to award attorney's fees under § 285 of the Patent Act. Specifically, AIA argues that when an award of attorney's fees is based in part or in whole on a party's state of mind, intent, or culpability, only a jury may decide those issues. We review de novo the question of whether a party is entitled to a jury trial. Tegal Corp. v. Tokyo Electron Am., Inc. , 257 F.3d 1331, 1339 (Fed. Cir. 2001).

A litigant has a right to a jury trial if provided by statute, or if required by the Seventh Amendment. See Feltner v. Columbia Pictures Television, Inc. , 523 U.S. 340, 345, 118 S.Ct. 1279, 140 L.Ed.2d 438 (1998). With no right to a jury trial provided in the statute, AIA relies solely on the Seventh Amendment.

The Seventh Amendment preserves the right to a jury trial for "[s]uits at common law." U.S. Const. amend. VII. The phrase "suits at common law" refers to suits in which only legal rights and remedies were at issue, as opposed to equitable rights and remedies. Granfinanciera, S.A. v. Nordberg , 492 U.S. 33, 41, 109 S.Ct. 2782, 106 L.Ed.2d 26 (1989). A legal remedy requires a jury trial on demand, while an equitable remedy does not implicate the right to a jury trial. Curtis v. Loether , 415 U.S. 189, 196 n.11, 94 S.Ct. 1005, 39 L.Ed.2d 260 (1974). A two-step inquiry determines whether a modern statutory cause of action involves only legal rights and remedies. Tull v. United States , 481 U.S. 412, 417–18, 107 S.Ct. 1831, 95 L.Ed.2d 365 (1987). First, we must "compare the statutory action to 18th-century actions brought in the courts of England prior to the merger of the courts of law and equity." Id. at 417, 107 S.Ct. 1831. "Second, we examine the remedy sought and determine whether it is legal or equitable in nature." Id . at 417–18, 107 S.Ct. 1831. The Supreme Court has stressed the second step of this test is the more important of the two. Chauffeurs, Teamsters & Helpers, Local No. 391 v. Terry , 494 U.S. 558, 565, 110 S.Ct. 1339, 108 L.Ed.2d 519 (1990) ("The second inquiry is the more important in our analysis.").

Turning to the first step, the nature of the claim, English courts for centuries have allowed claims for attorney's fees in both the courts of law and equity. Arthur L. Goodhart, Costs , 38 Yale L. J. 849, 851–54 (1929). But when brought in the courts of law, judges, not juries, determined attorney's fees. Id . Therefore, since either a judge in the court of law or an equity court would determine attorney's fees, this implies that attorney's fees generally do not involve legal rights.

As to the second step, the nature of the remedy, the fact that the relief sought is monetary does not necessarily make the remedy "legal." Terry , 494 U.S. at 570, 110 S.Ct. 1339. In the context of attorney's fees, when attorney's fees are themselves part of the merits of an action, they are regarded as a "legal" remedy. For example, a lawyer's fee claim against a client is a question for the jury, Simler v. Conner , 372 U.S. 221, 223, 83 S.Ct. 609, 9 L.Ed.2d 691 (1963) (per curiam), and a claim for attorney's fees under a contractual indemnification provision is a contractual "legal right" that is also a question for the jury, McGuire v. Russell Miller, Inc. , 1 F.3d 1306, 1315–16 (2d Cir. 1993). By contrast, when attorney's fees are awarded pursuant to a statutory prevailing party provision, they are regarded as an "equitable" remedy because they raise "issues...